Perspective Therapeutics — 3Q 2026 Earnings Summary

Perspective Therapeutics reported a net loss of $32.4 million for the third quarter of 2026, with cash and short-term investments totaling approximately $202 million as of September 30, 2026. The company's lead candidate, bamzireotide navoxetan, demonstrated strong clinical efficacy in neuroendocrine tumors, prompting plans for an End-of-Phase 2 meeting with the FDA in the first quarter of 2027. Additionally, PSV359 received Fast Track designation from the FDA for FAP-positive solitary fibrous tumors, and a collaboration with Merck was established to evaluate the drug in combination with Keytruda for lung and colorectal cancers. The firm also observed meaningful antitumor activity for lapemelanotide zapixetar in metastatic melanoma and expects construction of its Chicago manufacturing facility to be completed in early 2027.